You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

CORPORATE

A chat with Val Romberg

Kedrion Biopharma's new CEO shares his views

read more 

EVENTS

Turkey, Kedrion supports the XVII International Congress on Hemophilia

The present and future role of Factor VIII at the center of the symposium supported by Kedrion

read more 

EVENTS

Kedrion is one of the main sponsors of the National SISET Conference

The company sponsors two scientific lectures, a testament to its close ties with the world of medicine and science

read more 
  1. EVENTS - 17-10-2016

    Kedrion took part in the 17th ESID Meeting with 44 international guests

    The conference focused on new insights into PIDs’ diagnosis and therapies

    read more 
  2. EVENTS - 23-09-2016

    Pharmaceutical digitization: how to improve patient care and engagement

    Kedrion Biopharma Advisor Prof. Albert Farrugia lectures at "The Future of Science" Conference in Venice, Italy

    read more 
  3. PLASMA & BIOTHERAPIES - 16-09-2016

    Humanitarian Factor IX donation to Afghanistan

    Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries

    read more 
  4. PLASMA & BIOTHERAPIES - 13-09-2016

    Kedrion and Kamada seek FDA approval of IgG as a post-exposure treatment

    BLA has been submitted on September 1, 2016. Companies planning for decision from FDA in mid-2017

    read more 

Pages

For more information please contact: pressoffice@kedrion.com